3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabAtrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Atrophy, Spinal, Type II, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinal Muscular Atrophies of Childhood, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, motor neuron disorder, muscular atrophy, nervous system disorder, neurodegenerative disease, neuromuscular disease, proximal spinal muscular atrophy, spinal cord disorder, spinal muscular atrophy, spinal muscular atrophy, type IIIActive, not recruitingPhase 32026-09-01NCT05626855
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesAlport syndrome, Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hemorrhage, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, Urogenital Abnormalities, Urogenital Diseases, autoimmune disease, blood coagulation disease, cardiovascular disorder, connective tissue disorder, focal segmental glomerulosclerosis, glomerulonephritis, hematologic disorder, hemorrhagic disease, hereditary nephritis, immune system disorder, immunoglobulin A vasculitis, kidney disorder, macular corneal dystrophy, minimal change disease, nephritis, nephrosis, purpura, skin disorder, skin vascular disease, type III hypersensitivity disease, urinary system disorder, vascular disorder, vascular hemostatic disease, vasculitisRecruitingPhase 22026-05-12NCT05003986
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Primary Immunodeficiency Diseases, hereditary disease, immune system disorder, inborn error of immunityActive, not recruitingPhase 32026-04-08NCT06076642